Perceptive Advisors IOVA Position
Exited6-Fund ConvergencePerceptive Advisors exited their position in Iovance Biotherapeutics Inc. (IOVA) in Q2 2025, after holding the stock for 10 quarters.
The position was first reported in Q1 2023 and has been tracked across 10 quarterly 13F filings.
IOVA is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for E7 TCR-T cells in 168 days (Oct 1, 2026), making the timing of Perceptive's position particularly relevant.
Short interest stands at 30.1% of float with 5.2 days to cover, indicating significant bearish positioning against the stock.
About Iovance Biotherapeutics Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Full company profile →Short Interest
30.1%
5.2 days to cover
Perceptive Advisors IOVA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q2 2025 | Exited | 0 | -12,711,788 | $0 |
| Q1 2025 | Decreased | 12,711,788 | -9,400,478 | $42.3M |
| Q4 2024 | Decreased | 22,112,266 | -4,505,443 | $163.6M |
| Q3 2024 | Increased | 26,617,709 | +684,567 | $249.9M |
| Q2 2024 | Increased | 25,933,142 | +6,660,151 | $208.0M |
| Q1 2024 | Increased | 19,272,991 | +7,293,576 | $285.6M |
| Q4 2023 | Increased | 11,979,415 | +16,477 | $97.4M |
| Q3 2023 | Decreased | 11,962,938 | -2,073,472 | $54.4M |
| Q2 2023 | Decreased | 14,036,410 | -1,303,325 | $98.8M |
| Q1 2023 | New | 15,339,735 | +15,339,735 | $93.7M |
Frequently Asked Questions
Does Perceptive Advisors own IOVA?
No. Perceptive Advisors exited their position in Iovance Biotherapeutics Inc. (IOVA) in Q2 2025. They previously held the stock for 10 quarters.
How many hedge funds own IOVA?
6 specialist biotech hedge funds currently hold IOVA, including Avoro Capital Advisors, OrbiMed Advisors, Boxer Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy IOVA?
Perceptive Advisors's position in IOVA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's IOVA position increasing or decreasing?
Perceptive Advisors completely exited their IOVA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IOVACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →